


USE OF THROMBOPOETIN RECEPTOR AGONISTS (TPO RAs) AND FOSTAMATINIB IN THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN ADULTS

Approved by NHS Surrey Heartlands ICS Area Prescribing Committee — October 2024



Notes:

1. NICE only recommends switching from a TPO-RA to fostamatinib.
2. Locally commissioned policy allows one switch only between TPO-RAs before progressing to fostamatinib.

References:

1. NICE Technical Guidance TA293, TA853, TA221 and TA835 Available at: <https://www.nice.org.uk>
2. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Available at: Updated international consensus report on the investigation and management of primary immune thrombocytopenia | Blood Advances | American Society of Hematology (ashpublications.org)
3. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Available at: American Society of Hematology 2019 guidelines for immune thrombocytopenia | Blood Advances | American Society of Hematology (ashpublications.org)

Developed with reference to 'Derbyshire commissioning guidance for treating chronic immune (idiopathic) or refractory chronic thrombocytopenic purpura (ITP)' from Derbyshire Joint Area Prescribing Committee (JAPC), updated April 2023.